Skip to main content Skip to navigation
PE Mouse Anti-Human CD79a
Product Details
Down Arrow Up Arrow


BD™
CD79a, immunoglobulin-associated alpha ; CD79A; Ig-alpha; IGA; Igα; MB-1
Human
Mouse BALB/c IgG1, κ
Human CD79a Peptide
Flow cytometry
1.6 μg/mL
20 μL
V cB017
973
Phosphate buffered saline with gelatin and 0.1% sodium azide.
RUO


Preparation And Storage

Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.

340579 Rev. 1
Antibody Details
Down Arrow Up Arrow
HM47

The CD79a antibody, clone HM47, is derived from the hybridization of Sp2/0 mouse myeloma cells with spleen cells from BALB/c mice immunized with a synthetic peptide conjugated to thyroglobulin. The peptide has the sequence representing amino acids 202–216 inclusive as deduced from the human mb-1 cDNA sequence.

The CD79a antibody recognizes the cytoplasmic domain of a 47-kilodalton (kDa) membrane glycoprotein present on B lymphocytes.

340579 Rev. 1
Format Details
Down Arrow Up Arrow
PE
R-Phycoerythrin (PE), is part of the BD family of Phycobiliprotein dyes. This fluorochrome is a multimeric fluorescent phycobiliprotein with excitation maximum (Ex Max) of 496 nm and 566 nm and an emission maximum (Em Max) at 576 nm. PE is designed to be excited by the Blue (488 nm), Green (532 nm) and Yellow-Green (561 nm) lasers and detected using an optical filter centered near 575 nm (e.g., a 575/26-nm bandpass filter). As PE is excited by multiple lasers, this can result in cross-laser excitation and fluorescence spillover on instruments with various combinations of Blue, Green, and Yellow-Green lasers. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
PE
Yellow-Green 488 nm, 532 nm, 561 nm
496 nm, 566 nm
576 nm
340579 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (7)

  1. Astsaturov IA, Matutes E, Morilla R, et al. Differential expression of B29 (CD79b) and mb-1 (CD79a) proteins in acute lymphoblastic leukaemia. Leukemia. 1996; 10(5):769-773. (Biology). View Reference
  2. Centers for Disease Control. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in healthcare settings. MMWR. 1988; 37:377-388. (Biology).
  3. Clinical and Laboratory Standards Institute. 2005. (Biology).
  4. Engel P, Wagner N, Tedder TF. Schlossman SF, Boumsell L, Gilks W, et al, ed. Leucocyte Typing V: White Cell Differentiation Antigens. New York, NY: Oxford University Press; 1995:667-679.
  5. Mason DY, Cordell JL, Tse AG, et al. The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. J Immunol. 1991; 147(11):2474-2482. (Biology). View Reference
  6. Sakaguchi N, Kashiwamura S, Kimoto M, Thalmann P, Melchers F. B lymphocyte lineage-restricted expression of mb-1, a gene with CD3-like structural properties. EMBO J. 1988; 7(11):3457-3464. (Biology). View Reference
  7. Verschuren MC, Comans-Bitter WM, Kapteijn CA, et al. Transcription and protein expression of mb-1 and B29 genes in human hematopoietic malignancies and cell lines. Leukemia. 1993; 7:1939-1947. (Biology).
View All (7) View Less
340579 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Refer to manufacturer's instructions for use and related User Manuals and Technical Data Sheets before using this product as described.

Comparisons, where applicable, are made against older BD technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.